Factors affecting 18F FDOPA standardized uptake value in patients with primary brain tumors after treatment

Chiaravalloti, Agostino; Fiorentini, Alessandro; Villani, Veronica; Carapella, Carmine Maria; Pace, Andrea; Pietro, Barbara Di; Russo, Carmen Di; Palumbo, Barbara; Floris, Roberto; Schillaci, Orazio

doi:10.1016/j.nucmedbio.2015.01.002

Cited by 28 publications

(24 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chiaravalloti et al . [ 20 ] showed that [18F] FDOPA SUV may be affected by treatment, and in particular, by radiotherapy. They demonstrated a significant relationship between the interval from RT to the PET/CT scan for both SUVmax and SUVmean with a higher SUV being related to a smaller interval from RT.…”

Section: Discussionmentioning

confidence: 99%

[18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression

et al. 2017

View full text Add to dashboard Cite

[18F]-FDOPA is a labeled amino acid (AA) analog used for positron emission tomography (PET) which is gaining increasing interest in the evaluation of brain tumors (BT). The AA-transporter LAT1 has been shown to be involved in [18F]-FDOPA uptake. The aim of this study was to determine whether the [18F]-FDOPA uptake was correlated with level of LAT1 expression in BT. Twenty-eight BT (including 19 gliomas and 9 metastases) were investigated by [18F]-FDOPA-PET prior to surgery and by anti-LAT1 immunohistochemistry on surgical specimens. The quantitative [18F]-FDOPA measured parameters were SUVmax, SUVmean and SUVpeak. LAT1 expression was quantified using a score (0 to 400). A significant [18F]-FDOPA uptake was associated with a LAT1 score ≥ 100 (p = 0.02) but there was no linear correlation between intensity of [18F]-FDOPA uptake and score of LAT1 expression whatever the parameters considered. LAT1 expression alone is not sufficient to explain variation of intensity of [18F]-FDOPA uptake in BT.

show abstract

Section: Discussionmentioning

confidence: 99%

[18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression

et al. 2017

View full text Add to dashboard Cite

show abstract

“…From the VOI, the maximum standardized uptake value for the site of recurrence (SUVmax lesion) was calculated on a dedicated workstation (version 4.4, Advantage Workstation, GE Healthcare, Chicago, IL, USA). No one of the patients of this study had PBT in the occipital region; therefore, this site was chosen for SUVmax calculation for the background (SUVmax occ), obtained using a standard VOI of 1.5 cm × 1.5 cm ×1.5 cm, placed on the occipital lobe as proposed in a previous study of Chiaravalloti et al [ 17 ].…”

Section: Methodsmentioning

confidence: 99%

MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [18F]FDOPA Uptake in Primary Brain Tumors

Cimini

Chiaravalloti

Ricci

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

The aim of our study was to investigate the effects of methylation of O⁶-methylguanine-DNA methyltransferase promoter (MGMTp) and isocitrate dehydrogenase 1 (IDH 1) mutations on amino acid metabolism evaluated with 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine ([18F] FDOPA) positron emission tomography/computed tomography (PET/CT). Seventy-two patients with primary brain tumors were enrolled in the study (33 women and 39 men; mean age 44 ± 12 years old). All of them were subjected to PET/CT examination after surgical treatment. Of them, 29 (40.3%) were affected by grade II glioma and 43 (59.7%) by grade III. PET/CT was scored as positive or negative and standardized uptake value ratio (SUVr) was calculated as the ratio between SUVmax of the lesion vs that of the background. Statistical analysis was performed with the Mann–Whitney U test. Methylation of MGMTp was detectable in 61 out of the 72 patients examinated. Mean SUVr in patients without methylation of MGMTp was 1.44 ± 0,38 vs. 1.35 ± 0.48 of patients with methylation (p = 0.15). Data on IDH1 mutations were available for 43 subjects; of them, 31 are IDH-mutant. Mean SUVr was 1.38 ± 0.51 in patients IDH mutant and 1.46 ± 0.56 in patients IDH wild type. MGMTp methylation and IDH1 mutations do not affect [18F] FDOPA uptake in primary brain tumors and therefore cannot be assessed or predicted by radiopharmaceutical uptake parameters.

show abstract

“…PET acquisition started 15 min after the injection. 3 Together with the papers previously cited, the report of these cases suggests that 18 F FDOPA could be considered in addition to conventional imaging for the metabolic evaluation of brain metastatic lesions both at staging and re-staging.…”

mentioning

confidence: 74%

18F FDOPA uptake in brain metastasis of breast cancer

Chiaravalloti

Floris

Schillaci

2016

Revista Española de Medicina Nuclear e Imagen Molecular

View full text Add to dashboard Cite

show abstract

Factors affecting 18F FDOPA standardized uptake value in patients with primary brain tumors after treatment

Cited by 28 publications

References 15 publications

[18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression

[18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression

MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [18F]FDOPA Uptake in Primary Brain Tumors

18F FDOPA uptake in brain metastasis of breast cancer

Contact Info

Product

Resources

About